Abstract
Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago. In addition to short-term use for pain and fever relief, regular use of aspirin has been shown to reduce the risk of cardiovascular diseases and strokes. The issue of regular aspirin use in cancer prevention is definitely promising, which has been supported by growing evidence from a number of observational studies and post-trial follow-up data. Among all cancers, aspirin is showing to be the most effective in reducing the risk of colorectal cancer, and even at lower doses demonstrates a 30-40% effectiveness in preventing colorectal cancer. Esophagus and stomach cancers are two cancers getting increased attention from emerging evidence of meta-analyses. Given the common side effects of aspirin, such as gastrointestinal complications, whether it is ready to take aspirin regularly for general population remains controversial since more studies are needed to clarify the net balance between harm and benefit. The decision might become more complicated since recently one molecular epidemiology study showed that different genetic traits may impact the effect of aspirin on colorectal cancer. Here we summarize recent evidence from meta-analyses related to gastrointestinal cancers. We reviewed updated observational studies and post-trial follow up data from randomized controlled trials focusing on the role of aspirin in the incidence and mortality of gastrointestinal cancers.
Keywords: Aspirin, gastrointestinal cancer, primary prevention, mortality.
Current Pharmaceutical Design
Title:Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Volume: 21 Issue: 35
Author(s): Wen-Kuan Huang, Hui-Tzu Tu and Lai-Chu See
Affiliation:
Keywords: Aspirin, gastrointestinal cancer, primary prevention, mortality.
Abstract: Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago. In addition to short-term use for pain and fever relief, regular use of aspirin has been shown to reduce the risk of cardiovascular diseases and strokes. The issue of regular aspirin use in cancer prevention is definitely promising, which has been supported by growing evidence from a number of observational studies and post-trial follow-up data. Among all cancers, aspirin is showing to be the most effective in reducing the risk of colorectal cancer, and even at lower doses demonstrates a 30-40% effectiveness in preventing colorectal cancer. Esophagus and stomach cancers are two cancers getting increased attention from emerging evidence of meta-analyses. Given the common side effects of aspirin, such as gastrointestinal complications, whether it is ready to take aspirin regularly for general population remains controversial since more studies are needed to clarify the net balance between harm and benefit. The decision might become more complicated since recently one molecular epidemiology study showed that different genetic traits may impact the effect of aspirin on colorectal cancer. Here we summarize recent evidence from meta-analyses related to gastrointestinal cancers. We reviewed updated observational studies and post-trial follow up data from randomized controlled trials focusing on the role of aspirin in the incidence and mortality of gastrointestinal cancers.
Export Options
About this article
Cite this article as:
Huang Wen-Kuan, Tu Hui-Tzu and See Lai-Chu, Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915110450
DOI https://dx.doi.org/10.2174/1381612821666150915110450 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A New Series of Antileukemic Agents: Design, Synthesis, <i>In Vitro</i> and <i>In Silico</i> Evaluation of Thiazole-Based ABL1 Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication
Current Topics in Medicinal Chemistry Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Prevention of Capecitabine Toxicity Using a 5-FU Test Dose
Clinical Cancer Drugs Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors
Current Topics in Medicinal Chemistry Editorial: New Strategies and Applications for Drugs Targeting EGFR and c-Met
Current Drug Targets Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Preparation and Characterization of Chitosan Monomer/Organic Rectorite Nanocomposite
Current Nanoscience Identification of Bone Metastasis-associated Genes of Gastric Cancer by Genome-wide Transcriptional Profiling
Current Bioinformatics Current and Future Applications of Probiotics
Current Nutrition & Food Science Recent Advances in Combretastatin A-4 Inspired Inhibitors of Tubulin Polymerization: An Update
Current Medicinal Chemistry 6-Chloro-7-methyl-3', 4'-dimethoxyflavone – a Potent Selective COX-2 Inhibitor
Medicinal Chemistry Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors
Current Enzyme Inhibition Peptide based Molecules as Protein-Protein Interaction Inhibitors: Tools for Chemical Genetics and Therapy
Current Chemical Biology Metal Complexes of Natural Product Like-compounds with Antitumor Activity
Anti-Cancer Agents in Medicinal Chemistry Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry